Meeting
2017 ASCO Annual Meeting
ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.
Authors
Melissa Lynne Johnson
Sarah Cannon Research Institute, Nashville, TN
Melissa Lynne Johnson , Rene Gonzalez , Mateusz Opyrchal , Dmitry Gabrilovich , Peter Ordentlich , Susan Brouwer , Serap Sankoh , Emmett V. Schmidt , Michael L. Meyers , Sanjiv S. Agarwala
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02437136
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9529)
DOI
10.1200/JCO.2017.35.15_suppl.9529
Abstract #
9529
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
First Author: Nikhil Shukla
Poster
2018 ASCO Annual Meeting
ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.
First Author: Nilofer Saba Azad
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya
Poster
2016 ASCO Annual Meeting
Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
First Author: David R. Spigel